|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Suzuki M, Iizasa T, Nakajima T, Kubo R,
Iyoda A, Hiroshima K, Nakatani Y and Fujisawa T: Aberrant
methylation of IL-12Rβ2 gene in lung cancer. J Thorac oncol. 2 8
Suppl 4:S4932007. View Article : Google Scholar
|
|
3
|
Orlova A, Hofström C, Strand J, Varasteh
Z, Sandstrom M, Andersson K, Tolmachev V and Gräslund T:
[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for
visualization of insulin-like growth factor-1 receptor expression
in malignant tumours. Eur J Nucl Med Mol Imaging. 40:439–449. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nose N, Uramoto H, Iwata T, Hanagiri T and
Yasumoto K: Expression of estrogen receptor beta predicts a
clinical response and longer progression-free survival after
treatment with EGFR-TKI for adenocarcinoma of the lung. Lung
Cancer. 71:350–355. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Torres-Arzayus MI, Zhao J, Bronson R and
Brown M: Estrogen-dependent and estrogen-independent mechanisms
contribute to AIB1-mediated tumor formation. Cancer Res.
70:4102–4111. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Airoldi I, Cocco C, Di Carlo E, Disarò S,
Ognio E, Basso G and Pistoia V: Methylation of the IL-12Rbeta2 gene
as novel tumor escape mechanism for pediatric B-acute lymphoblastic
leukemia cells. Cancer Res. 66:3978–3980. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Airoldi I, Di Carlo E, Banelli B, Moserle
L, Cocco C, Pezzolo A, Sorrentino C, Rossi E, Romani M, Amadori A
and Pistoia V: The IL-12Rbeta2 gene functions as a tumor suppressor
in human B cell malignancies. J Clin Invest. 113:1651–1659. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Airoldi I, Di Carlo E, Cocco C, Caci E,
Cilli M, Sorrentino C, Sozzi G, Ferrini S, Rosini S, Bertolini G,
et al: IL-12 can target human lung adenocarcinoma cells and normal
bronchial epithelial cells surrounding tumor lesions. PLoS One.
4:e61192009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Suzuki M, Iizasa T, Nakajima T, Kubo R,
Iyoda A, Hiroshima K, Nakatani Y and Fujisawa T: Aberrant
methylation of IL-12Rbeta2 gene in lung adenocarcinoma cells is
associated with unfavorable prognosis. Ann Surg Oncol.
14:2636–2642. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li H, Cao MY, Lee Y, Lee V, Feng N,
Benatar T, Jin H, Wang M, Der S, Wright JA and Young AH: Virulizin,
a novel immunotherapy agent, activates NK cells through induction
of IL-12 expression in macrophages. Cancer Immunol Immunother.
54:1115–1126. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lecocq M, Detry B, Guisset A and Pilette
C: FcαRI-mediated inhibition of IL-12 production and priming by
IFN-γ of human monocytes and dendritic cells. J Immunol.
190:2362–2371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kontoyiannis D, Kotlyarov A, Carballo E,
Alexopoulou L, Blackshear PJ, Gaestel M, Davis R, Flavell R and
Kollias G: Interleukin-10 targets p38 MAPK to modulate
ARE-dependent TNF mRNA translation and limit intestinal pathology.
EMBO J. 20:3760–3770. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fahmi A, Smart N, Punn A, Jabr R, Marber M
and Heads R: p42/p44-MAPK and PI3K are sufficient for IL-6 family
cytokines/gp130 to signal to hypertrophy and survival in
cardiomyocytes in the absence of JAK/STAT activation. Cell Signal.
25:898–909. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Korhonen R, Huotari N, Hömmö T, Leppänen T
and Moilanen E: The expression of interleukin-12 is increased by
MAP kinase phosphatase-1 through a mechanism related to interferon
regulatory factor 1. Mol Immunol. 51:219–226. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cuenda A and Rousseau S: p38 MAP-kinases
pathway regulation, function and role in human diseases. Biochim
Biophys Acta. 1773:1358–1375. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y,
Xu J, Hong B, Zhang M, Lin P, et al: p38 MAPK in myeloma cells
regulates osteoclast and osteoblast activity and induces bone
destruction. Cancer Res. 72:6393–6402. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tanaka Y, Gavrielides MV, Mitsuuchi Y,
Fujii T and Kazanietz MG: Protein kinase C promotes apoptosis in
LNCaP prostate cancer cells through activation of p38 MAPK and
inhibition of the Akt survival pathway. J Biol Chem.
278:33753–33762. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Slawinska-Brych A, Zdzisinska B,
Mizerska-Dudka M and Kandefer-Szerszen M: Induction of apoptosis in
multiple myeloma cells by a statin-thalidomide combination can be
enhanced by p38 MAPK inhibition. Leuk Res. 37:586–594. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen KH, Hung SH, Yin LT, Huang CS, Chao
CH, Liu CL and Shih YW: Acacetin, a flavonoid, inhibits the
invasion and migration of human prostate cancer DU145 cells via
inactivation of the p38 MAPK signaling pathway. Mol Cell Biochem.
333:279–291. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koul HK, Pal M and Koul S: Role of p38 MAP
kinase signal transduction in solid tumors. Genes Cancer.
4:342–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pietras RJ, Marquez DC, Chen HW, Tsai E,
Weinberg O and Fishbein M: Estrogen and growth factor receptor
interactions in human breast and non-small cell lung cancer cells.
Steroids. 70:372–381. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kawasaki H, Altieri DC, Lu CD, Toyoda M,
Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin
predicts shorter survival rates in colorectal cancer. Cancer Res.
58:5071–5074. 1998.PubMed/NCBI
|
|
23
|
Shaaban AM, Green AR, Karthik S, Alizadeh
Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders
PT, et al: Nuclear and cytoplasmic expression of ERbeta1, ERbeta2,
and ERbeta5 identifies distinct prognostic outcome for breast
cancer patients. Clin Cancer Res. 14:5228–5235. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chi A, Chen X, Chirala M and Younes M:
Differential expression of estrogen receptor beta isoforms in human
breast cancer tissue. Anticancer Res. 23:211–216. 2003.PubMed/NCBI
|
|
25
|
Liu ZG, Jiao XY, Chen ZG, Feng K and Luo
HH: Estrogen receptorβ2 regulates interlukin-12 receptorβ2
expression via p38 mitogen-activated protein kinase signaling and
inhibits non-small-cell lung cancer proliferation and invasion. Mol
Med Rep. 12:248–254. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kondadasula SV, Roda JM, Parihar R, Yu J,
Lehman A, Caligiuri MA, Tridandapani S, Burry RW and Carson WE III:
Colocalization of the IL-12 receptor and FcgammaRIIIa to natural
killer cell lipid rafts leads to activation of ERK and enhanced
production of interferon-gamma. Blood. 111:4173–4183. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jana M, Dasgupta S, Pal U and Pahan K:
IL-12 p40 homodimer, the so-called biologically inactive molecule,
induces nitric oxide synthase in microglia via IL-12R beta 1. Glia.
57:1553–1565. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pan SH, Chao YC, Hung PF, Chen HY, Yang
SC, Chang YL, Wu CT, Chang CC, Wang WL, Chan WK, et al: The ability
of LCRMP-1 to promote cancer invasion by enhancing filopodia
formation is antagonized by CRMP-1. J Clin Invest. 121:3189–3205.
2011. View
Article : Google Scholar : PubMed/NCBI
|
